Celltrion wins conditional nod for Regkirona in Switzerland

Korea Biomedical Review

14 January 2022 - Celltrion said that Swiss Medic, Switzerland’s drug administration, has temporary authorisation for Regkirona (regdanvimab).

Celltrion submitted the results of large-scale global phase 3 clinical trials and preclinical data on various variants, including the Delta, to the Swiss Medic, which granted temporary authorisation for using the treatment for adult patients with confirmed COVID-19 who do not need supplemental oxygen and are highly likely to become seriously ill.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder